TrialTrials2021

Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2.

Wendy Holman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.